ALA going from strength to strength when looking at their sp...

ALA going from strength to strength when looking at their sp with ZERO clinical progress. Valued now about $160m without their, about $5m cash.

CHM hasn't had any negative clinical news, only 1 pause in that AML trial due to a lack of university staff and some delays to roll out the GBM trial due to lack of specialists. On top of that, complete responses in their NK-trials and disease control in their GBM trial, which is phenomenal, and yet it is valued almost ZERO. RAD is valued even less than their cash at hand.

Fact is, if the right funds are selected for a cap raising then there isn't just money easily to be picked up, like ALA did, the sp won't even suffer as the participants won't sell their shares for up to 50% less than they bought them for as happened here and actually is at RAD.

I just hope Hopper will finally understand the value of the CHM assets and will demand an appropriate price for it. If ALA's Baker, who Hopper now seems to regard as useless, has been able to sell ALA's iNKT tech based on just pre-clinical data, then Hopper MUST be able to do at least the same for CHM.

Soon we will find out but I expect a terrible outcome. ALA shooting up today on nothing, probably already, even if it shouldn't be related, an indicator for the worst to come. One can only hope that I am the one who got it wrong.

GLTA